Baird analyst Brian Skorney reiterated a Neutral rating and $940.00 price target on Regeneron Pharma (NASDAQ: REGN)The analyst comments "Incrementally ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Morgan Stanley Reiterates Overweight Rating on Regeneron Pharma (REGN)September 26, 2024 5:56 AM Truist Securities on Regeneron Pharma (REGN): 'Buying opportunity'September 24, 2024 2:18 PM Goldman Sachs Reiterates Buy Rating on Regeneron Pharma (REGN)September 24, 2024 5:28 AM U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.15%September 23, 2024 4:49 PM RBC Capital on Regeneron (REGN): 'We see potential earlier-than-expected launch of biosimilar product as incrementally negative to REGN's story'September 23, 2024 4:40 PM BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)September 23, 2024 4:00 PM Truist Securities on Regeneron Pharma (REGN): 'view the pressure on stock as an overreaction'September 23, 2024 3:40 PM Regeneron (REGN) Reports Dupixent Recommended for EU Approval by the CHMPSeptember 20, 2024 7:45 AM Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year OldSeptember 20, 2024 7:45 AM Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year oldSeptember 20, 2024 7:45 AM